Abstract 1407P
Background
Lymphocyte subsets play significant roles in the occurrence and progression of malignant tumors. CD3+CD4+, CD3+CD8+, CD16+CD56+ lymphocytes are important lymphocyte subsets in peripheral blood. Platinum-based chemotherapy is one of the standard treatments for advanced non-small-cell lung cancer (NSCLC). We aimed to explore the relationship between different subsets with the prognosis of platinum-based chemotherapy in advanced NSCLC.
Methods
A retrospective analysis of 428 advanced NSCLC patients diagnosed from January 2015 to June 2018 received platinum-based chemotherapy was conveyed. Peripheral blood was obtained one week before treatment and lymphocyte subsets were analyzed. Receiver operating characteristic (ROC) curves were used to determine the optimal cutoff values for lymphocytes subsets, and Kaplan-Meier method and Cox regression analysis were used to evaluate their predictive effects on prognosis.
Results
The optimal cutoff for CD3+CD4+, CD3+CD8+ and CD16+CD56+ subsets were 40.1, 22.1 and 15.2 with maximum area under curve (AUC) of ROC cureves, respectively. Univariate analysis showed that KPS, histological subtype, tumor differentiation, CD3+CD4+ subset, CD3+CD8+ subset and CD16+CD56+ subset were significantly associated with progression-free survival (PFS) and overall survival (OS). Furthermore, COX multivariate analysis showed that histological subtype (RR=0.525, p <0.001), tumor differentiation (RR=0.624, p <0.001), CD16+CD56+ subset (RR=1.414, p=0.003) were independent prognostic factors on PFS; age (RR=1.289, p=0.038), KPS score (RR=0.666, p = 0.026), histological subtype (RR= 0.339, p <0.001), tumor differentiation (RR=0.611, p <0.001), EGFR status (no mutation vs. mutation) (RR=0.459, p <0.001), CD3+CD4+ subset (RR=1.416, p= 0.008), CD3+CD8+ subset (RR=1.334, p = 0.021) were independent risk factors for OS.
Conclusions
CD3+CD4+ and CD3+CD8+ lymphocyte subsets were both reliable independent biomarkers for predicting OS in advanced NSCLC patients treated with platinum-based chemotherapy. CD16+CD56+ lymphocyte subset was not an independent prognostic indicator.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China, 81501981.
Disclosure
All authors have declared no conflicts of interest.